However, additional driver mutations (i.e., tyrosine kinase mutations) causing proliferative AML clones may arise when the blasts phenotypically express CD33 [69]; therefore, GO may eliminate the proliferative blast cells and spare CD33-negative pre-leukemic cells. This evidence concerns the gene CD33 and acute myeloid leukemia.